Overview
Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)
Status:
Completed
Completed
Trial end date:
2006-11-01
2006-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is designed to compare a range of doses of GW856553 versus placebo on the biomarkers associated with rheumatoid arthritisPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
GlaxoSmithKline
Criteria
Inclusion criteria:- Must have a diagnosis of RA according to the revised 1987 criteria of the American
College of Rheumatology.
- Must have 3 or more swollen or 3 or more tender/painful joints at screening.
- Must be on stable weekly methotrexate (2.5mg-25mg) for at least eight weeks prior to
screening.
Exclusion criteria:
- Must not be morbidly obese.